Valeant Pharmaceuticals

When the Wolves Bite: Two Billionaires, One Company, and an Epic Wall Street Battle

by Scott Wapner  · 23 Apr 2018  · 302pp  · 80,287 words

, 168, 169, 171, 180, 182, 183, 184, 187, 188, 195, 197, 211 Kennedy Slide on Wall Street (1962), 117 See also Herbalife: stock prices of; Valeant pharmaceutical company: stock prices of Shaw, Bryan, 133 short selling, 10, 12, 13, 30, 31, 59, 62, 63, 83, 108, 127, 147, 170, 174 of Herbalife

The Myth of Capitalism: Monopolies and the Death of Competition

by Jonathan Tepper  · 20 Nov 2018  · 417pp  · 97,577 words

in 2006, they sold the drugs to a small company called Aton, which began raising the prices. Then, in 2010, Aton sold the drugs to Valeant Pharmaceuticals. That is when prices soared. Valeant raised the list price to around $300,000 for a year's supply in the United States, or $25

…

-families/stories. 2. https://www.vanityfair.com/news/2016/06/the-valeant-meltdown-and-wall-streets-major-drug-problem. 3. https://en.wikipedia.org/wiki/Valeant_Pharmaceuticals. 4. https://www.nytimes.com/2016/07/31/business/how-valeant-cashed-in-twice-on-higher-drug-prices.html. 5. http://fortune.com/2016/10

Big Mistakes: The Best Investors and Their Worst Investments

by Michael Batnick  · 21 May 2018  · 198pp  · 53,264 words

back to its concentrated ways in short order. It was in that same report, ironically, that they introduced what would become an extraordinarily large position, Valeant Pharmaceuticals. They first began purchasing shares on April 28, 2010, at $16. Valeant gained 70% that year and it quickly became the fund's second largest

…

, 61 U.S. housing bubble, impact, 132 U.S. Steel, shares orders, 17 US stock portfolio, diversification, 109 U.S. stocks, intra‐year decline, 147 Valeant Pharmaceuticals, 113 Ackman targeting, 90 performance, S&P500 comparison, 113 shares, decline, 114 Valuation metrics, 160 Value at risk (VAR), 41–42 Value investing, function, 10

The Golden Passport: Harvard Business School, the Limits of Capitalism, and the Moral Failure of the MBA Elite

by Duff McDonald  · 24 Apr 2017  · 827pp  · 239,762 words

moral code.29 And, incidentally, defended through schoolyard taunts. When Berkshire Hathaway vice chairman Charlie Munger questioned the morality of one of Ackman’s holdings, Valeant Pharmaceuticals, in late 2015 after it had been accused of jacking up the prices of drugs to unaffordable levels, Ackman fired back that the soda made

…

distortion and, 10, 466, 575 Useem, Jerry, 572 Useem, Michael, 189 U.S. Treasury, 73, 74 U.S. War Department, 135–39 Uyterhoeven, Hugo, 153 Valeant Pharmaceuticals, 480, 481, 482 “Value Maximization, Stakeholder Theory, and The Corporate Objective Function” (Jensen), 373–74 Vanderblue, Homer, 73 Vanity Fair, 188, 519 Van Maanen, John

The Revolution That Wasn't: GameStop, Reddit, and the Fleecing of Small Investors

by Spencer Jakab  · 1 Feb 2022  · 420pp  · 94,064 words

. This isn’t the story of Gabe Plotkin versus Keith Gill—it was Bill Ackman and Andrew Left who duked it out in public over Valeant Pharmaceuticals four years earlier. A professional short seller, Left had identified what he correctly believed were improperly inflated sales at the Canadian company, once a hedge

…

, 161, 170 SEC and, 167–68 two-day period to settle trades, 204 U Uber, 105 unemployment, 71, 151 Ursus, 85 utilitarian products, 51 V Valeant Pharmaceuticals, 116–17, 120, 125 Van Bavel, Jay, 20, 36 VandaTrack, 139 VanEck, 158–59 Vanguard Group, 8, 32, 254, 257, 259 venture capitalists, 24 Vergara

Beyond Diversification: What Every Investor Needs to Know About Asset Allocation

by Sebastien Page  · 4 Nov 2020  · 367pp  · 97,136 words

Martin Shkreli, Turing’s young and brash CEO, the “pharma bro.”) Second, on September 28, Democrats in the US House of Representatives asked to subpoena Valeant Pharmaceuticals for documents on drug price increases.9 XLV volume on that day reached an all-time high. Both events threatened to put pressure on pharmaceuticals

…

, 19 US Treasury bonds, 11 Utility, 192, 198 Utility function: approximating, 203–207 inflection points in, 201–203 Utility maximization, 199–203 Utility theory, 199 Valeant Pharmaceuticals, 238 Valuation, 25–42, 267 and bond future returns, 39–42 building block model for, 28–39 and CAPM model, 12 and equity risk premium

Black Edge: Inside Information, Dirty Money, and the Quest to Bring Down the Most Wanted Man on Wall Street

by Sheelah Kolhatkar  · 7 Feb 2017  · 385pp  · 118,901 words

suit against SAC was dismissed in 2009 by a judge in New Jersey. In February 2010, SAC sued Biovail, which had been taken over by Valeant Pharmaceuticals, accusing it of vexatious litigation. Valeant and SAC settled the case in November 2010, with Valeant agreeing to pay $10 million to SAC to compensate

…

to the investigation. Susan Pulliam, “How Associates Helped Build Case,” The Wall Street Journal, October 20, 2009. Biovail’s lawsuit against SAC had been dismissed: Valeant Pharmaceuticals eventually bought Biovail, and in 2010 settled claims brought by SAC Capital for vexatious litigation by agreeing to pay SAC $10 million. Shira Ovide, “SAC

The Price of Time: The Real Story of Interest

by Edward Chancellor  · 15 Aug 2022  · 829pp  · 187,394 words

-Busch InBev (also controlled by the Brazilian 3G), cereal-maker Post Holdings, together with a number of healthcare companies. No platform company soared higher than Valeant Pharmaceuticals. The brainchild of Michael Pearson, a former McKinsey consultant, Valeant acquired more than twenty medical and drug businesses, including contact lens-maker Bausch & Lomb. The

…

on, 17; Proudhon-Bastiat debate on, xvii–xix, xxi, xxii, xxv, 9; in Renaissance world, 22–3; scholastic attack on, 18–20, 23–4, 25 Valeant Pharmaceuticals, 161, 168–9 Vancouver, 175 Veblen, Thorstein, Theory of Business Enterprise (1904), 158, 159, 166 Velde, François, 58*, 59 Venice, 22, 23 Vinci, Leonardo da

100 Baggers: Stocks That Return 100-To-1 and How to Find Them

by Christopher W Mayer  · 21 May 2018

.2 Pharmacyclics Inc 5.0 Nexstar Broadcasting Group 5.0 Questcor Pharmaceuticals Inc 5.0 Biogen Idec Inc 5.5 Time Warner Inc 6.0 Valeant Pharmaceuticals Intl 6.5 Dell Inc 7.2 L Brands Inc 7.3 Qualcomm Inc 7.3 Cisco Systems Inc 7.3 Emc Corp/MA 7

…

at Colfax. It was on fire for a while. The stock seems to be on sale now, off 30 percent from its high. • Mike Pearson, Valeant Pharmaceuticals (VRX). This one is controversial. There are some vocal critics who think Valeant’s business model is all sizzle and no steak. They also dispute

…

12/31/93 477 11.3 MONSTER BEVERAGE CORP 12/31/93 2,523 9.5 SVB FINANCIAL GROUP 12/31/93 174 25.2 VALEANT PHARMACEUTICALS INTL 12/31/94 815 6.5 ALEXION PHARMACEUTICALS INC 10/31/96 123 17.7 BP PRUDHOE BAY ROYALTY TRUST 12/31/96 141

Bad Blood: Secrets and Lies in a Silicon Valley Startup

by John Carreyrou  · 20 May 2018  · 359pp  · 110,488 words

, though it bore his name, was no longer his. He had sold it more than a decade earlier. It was now part of Canadian drugmaker Valeant Pharmaceuticals, he explained. The man placed a call and repeated what Fuisz had said. The response, conveyed by someone shouting on the other end of the

The Joys of Compounding: The Passionate Pursuit of Lifelong Learning, Revised and Updated

by Gautam Baid  · 1 Jun 2020  · 1,239pp  · 163,625 words

In Pursuit of the Perfect Portfolio: The Stories, Voices, and Key Insights of the Pioneers Who Shaped the Way We Invest

by Andrew W. Lo and Stephen R. Foerster  · 16 Aug 2021  · 542pp  · 145,022 words

Why Wall Street Matters

by William D. Cohan  · 27 Feb 2017  · 113pp  · 37,885 words